PNC Financial Services Group Inc. Sells 262 Shares of Repligen Co. (NASDAQ:RGEN)

PNC Financial Services Group Inc. cut its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 7.0% in the 4th quarter, HoldingsChannel reports. The fund owned 3,480 shares of the biotechnology company’s stock after selling 262 shares during the period. PNC Financial Services Group Inc.’s holdings in Repligen were worth $501,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Champlain Investment Partners LLC grew its position in Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after purchasing an additional 850,345 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Repligen in the 4th quarter worth about $52,492,000. Allspring Global Investments Holdings LLC grew its position in Repligen by 79.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock worth $65,395,000 after purchasing an additional 203,011 shares in the last quarter. DF Dent & Co. Inc. grew its position in Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after purchasing an additional 139,615 shares in the last quarter. Finally, Two Sigma Advisers LP grew its position in Repligen by 421.9% in the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after purchasing an additional 102,100 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Margaret Pax bought 250 shares of the stock in a transaction on Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Repligen Stock Performance

Shares of RGEN stock opened at $144.88 on Thursday. The stock has a market capitalization of $8.12 billion, a P/E ratio of -284.08, a PEG ratio of 4.54 and a beta of 0.95. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm’s 50 day moving average is $156.78 and its 200 day moving average is $148.46. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $200.23.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. On average, sell-side analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on RGEN shares. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Canaccord Genuity Group increased their target price on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st. TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. StockNews.com downgraded shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. Finally, Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Repligen has a consensus rating of “Hold” and a consensus target price of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.